BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel
CYTRX (NQ: CYTR)
3.180 USD  +0.035 (+1.11%)
Official Closing Price  /  Updated: 5:20 PM EDT, Apr 24, 2014  /  Add to My Watchlist      
(CYTR) Community Analysis from
Bulls REASONS TO BUY
Bears REASONS TO SELL
April 24, 2014
(Benzinga, 1/4/12)
Sickle cell disease is debilitating to millions of Americans, including Pittsburgh Steelers safety Ryan Clark. Although Clark only has one copy of the sickle cell gene -...(read more)
(Value Investing, 6/19/11)
Cytrx Corporation Investment Overview Cytrx, a micro, undervalued biopharmaceutical company, currently has three main high potential drugs in its pipeline. Recently, Bloomberg BusinessWeek highlighted the effectiveness of...(read more)
In another installment of highlighting various investment opportunities, today, I’m going to cover CytRx Corporation (ticker: CYTR).  As a biotech guy myself, I’m always interested in up and...(read more)
CytRx (CYTR) Company Overview

There is no analysis for CYTR yet. But you can go to Wikinvest to help create one!


Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here